NovaDel Names Henry Kwan, PhD Head Of Pharmaceutical Sciences
FLEMINGTON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (AMEX:NVD) announced that Henry Kwan, PhD joined the company as Head of
Pharmaceutical Sciences.
Most recently Dr. Kwan was Vice President, R&D and Regulatory Affairs for
Eurand, Inc., a specialty pharmaceutical company focused on drug delivery
technologies. Previously, Dr. Kwan served as Assistant Vice President,
Technical Services (North America), for Wyeth-Ayerst and as Vice President,
Reformulation and Pharmaceutical Technology (North America) for Warner-Lambert
(now Pfizer).
"Henry's 26 years' experience in the pharmaceutical industry in the areas of
dosage form development, product development, process scale-up, and regulatory
submission will make a timely and important contribution to NovaDel," said Gary
A. Shangold, MD, CEO and President of NovaDel. "We are at a critical juncture
whereby we are moving several of our tier I priority products into full
clinical development and we plan to add new lingual spray formulations to our
pipeline in 2005. Dr. Kwan's strong leadership skills will play a key role in
ensuring that our programs progress quickly, efficiently and at a high level of
quality." Major products Dr. Kwan helped to develop and submit for approval include
Claritin(R), Claritin D(R) 24, Afrin(R), Nasonex(R) and Intron(R) A.
Dr. Kwan holds a PhD in Pharmaceutical Chemistry from the University of
Michigan, and a Bachelor of Science cum laude in Chemistry from Marquette
University. He is a member of the American Association of Pharmaceutical
Scientists (AAPS).
Dr. Kwan resides in Summit, New Jersey.
About NovaDel
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and over-the-
counter drugs. The company's proprietary lingual spray technology delivery
system offers the patient the potential for (i) fast onset of action; (ii)
improved drug safety by reducing the required drug dosage and reducing side
effects; (iii) improved patient convenience and compliance; and (iv) enhanced
dosage reliability. The company plans to develop such products independently
and through collaborative arrangements with major pharmaceutical and biotech
companies. To find out more about NovaDel Pharma Inc. (AMEX:NVD), visit our
website at http://www.novadel.com/.
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the successful completion of its pilot pharmacokinetic
feasibility studies, the ability to develop products (independently and through
collaborative arrangements), the ability to commercialize and obtain FDA and
other regulatory approvals for products under development and the acceptance in
the marketplace for lingual spray products.. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission. In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.
Barry C. Cohen
VP Business & New Product Development
908 782-3431 x2160
NovaDel Pharma Inc.
Thomas Redington
203 222-7399
212 926-1733
DATASOURCE: NovaDel Pharma, Inc.
CONTACT: Barry C. Cohen, VP Business & New Product Development of NovaDel Pharma Inc., +1-908-782-3431 ext. 2160; or Thomas Redington, +1-203-222-7399, +1-212-926-1733, , for NovaDel Pharma Inc.
Web site: http://www.novadel.com/
|